date,title,source
Oct-22-18,DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration,GlobeNewswire
Oct-26-18,DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers,GlobeNewswire
Oct-30-18,"DBV Technologies Reports September 30, 2018 Cash Position",GlobeNewswire
Nov-07-18,DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company,GlobeNewswire
Nov-09-18,DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting,GlobeNewswire
Nov-20-18,DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children,GlobeNewswire
Dec-06-18,DBV Technologies: Monthly information regarding the total number of voting rights and total number of shares of the Company,GlobeNewswire
Dec-12-18,DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018,GlobeNewswire
Dec-19-18,DBV Technologies: DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age,GlobeNewswire
